Bellomo Tiffany R, Bramel Emily E, Lee Jiwoo, Urbut Sarah, Flores Alyssa, Yu Zhi, Koyama Satoshi, Truong Buu, Haidermota Sara, Eagleton Matthew J, Natarajan Pradeep, Patel Aniruddh P
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.R.B., E.E.B., J.L., S.U., A.F., Z.Y., S.K., B.T., S.H., P.N., A.P.P.).
Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA. (T.R.B., A.F., M.J.E.).
Circulation. 2025 Jul 28. doi: 10.1161/CIRCULATIONAHA.124.073579.
Despite current treatment strategies for atherosclerotic vascular disease focusing on lifestyle modification and lowering cholesterol, a significant residual risk of major atherosclerotic complication remains, prompting investigation into lipoprotein(a) (Lp(a)) as a potential predictive biomarker. The objective of this study was to determine the usefulness of Lp(a) in identifying patients at high risk of incident extracoronary atherosclerotic vascular disease and complications.
Data from 460 544 participants in the UK Biobank with prospectively measured Lp(a) concentrations were included in this analysis. Cox proportional hazards regressions modeled the associations of Lp(a) concentrations with incident peripheral artery disease (PAD) and incident carotid artery stenosis and progression to the first major adverse limb event and the first stroke, respectively.
Of the study participants, the median [interquartile range] age at study enrollment was 58 [51-64] years, 54.2% were male, 94.4% were European, 5.5% had diabetes, and 10.5% were smokers. Over a median follow-up time of 13.6 [12.9-14.4] years, 6347 (1.4%) and 1972 (0.43%) developed the first incidence of PAD and carotid stenosis, respectively. Among participants with prevalent PAD and carotid stenosis at enrollment, 196 (2.7%) and 67 (1.9%) progressed to the first incidence of major adverse limb event and stroke, respectively. Median Lp(a) concentrations were significantly different in those without atherosclerotic vascular disease at 19.5 nmol/L [7.6-73.5] compared with incident PAD at 25.3 nmol/L [8.3-107.3], progression to major adverse limb event at 33.3 nmol/L [8.7-158.2], incident carotid stenosis at 29.5 nmol/L [8.5-116.3], and carotid stenosis progression to stroke at 37.8 nmol/L [11.1-158.3]. The risk estimate per 75 nmol/L Lp(a) for incident PAD (hazard ratio [HR], 1.18 [95% CI, 1.15-1.20]; <0.0001) was similar to that for incident carotid stenosis (HR, 1.17 [95% CI, 1.13-1.20]; <0.0001). Among participants with PAD, those with high Lp(a) concentrations had 1.57 times the risk of developing major adverse limb event than participants with normal Lp(a) concentrations (95% CI, 1.14-2.16; =0.006). Among participants with carotid stenosis, participants had 1.40 times the risk of developing an ischemic stroke with high Lp(a) concentrations, although this was not significant (95% CI, 0.81-2.40; =0.228).
High concentrations of Lp(a) are associated with both incident extracoronary atherosclerotic vascular disease and progression to major complications.
尽管目前针对动脉粥样硬化性血管疾病的治疗策略侧重于生活方式改变和降低胆固醇,但主要动脉粥样硬化并发症的显著残余风险仍然存在,这促使人们对脂蛋白(a)(Lp(a))作为潜在的预测生物标志物进行研究。本研究的目的是确定Lp(a)在识别发生冠状动脉外动脉粥样硬化性血管疾病及并发症高风险患者中的作用。
本分析纳入了英国生物银行中460544名前瞻性测量了Lp(a)浓度的参与者的数据。Cox比例风险回归分别模拟了Lp(a)浓度与外周动脉疾病(PAD)、颈动脉狭窄的发生以及首次严重肢体不良事件和首次中风进展之间的关联。
在研究参与者中,入组时的中位年龄[四分位间距]为58[51 - 64]岁,54.2%为男性,94.4%为欧洲人,5.5%患有糖尿病,10.5%为吸烟者。在中位随访时间13.6[12.9 - 14.4]年期间,分别有6347例(1.4%)和1972例(0.43%)发生了首次PAD和颈动脉狭窄。在入组时患有PAD和颈动脉狭窄的参与者中,分别有196例(2.7%)和67例(1.9%)进展为首次严重肢体不良事件和中风。无动脉粥样硬化性血管疾病者的Lp(a)中位浓度为19.5 nmol/L[7.6 - 73.5],与发生PAD者的25.3 nmol/L[8.3 - 107.3]、进展为严重肢体不良事件者的33.3 nmol/L[8.7 - 158.2]、发生颈动脉狭窄者的29.5 nmol/L[8.5 - 116.3]以及颈动脉狭窄进展为中风者的37.8 nmol/L[11.1 - 158.3]有显著差异。每75 nmol/L Lp(a)发生PAD的风险估计值(风险比[HR],1.18[95%CI,1.15 - 1.20];<0.0001)与发生颈动脉狭窄的风险估计值相似(HR,1.17[95%CI,1.13 - 1.20];<0.0001)。在患有PAD的参与者中,Lp(a)浓度高者发生严重肢体不良事件的风险是Lp(a)浓度正常者的1.57倍(95%CI,1.14 - 2.16;P = 0.006)。在患有颈动脉狭窄的参与者中,Lp(a)浓度高者发生缺血性中风的风险是其1.40倍,尽管这一差异不显著(95%CI,0.81 - 2.40;P = 0.228)。
高浓度的Lp(a)与冠状动脉外动脉粥样硬化性血管疾病的发生以及进展为主要并发症均相关。